In:
Science, American Association for the Advancement of Science (AAAS), Vol. 357, No. 6354 ( 2017-09), p. 936-936
Abstract:
The genomics era has had a profound impact on life science research, leading to significant developments such as the use of expression quantitative trait loci (eQTLs), which link polymorphisms in single genes to quantifiable changes in gene expression associated with specific diseases. As the end products and biological effectors of gene expression, proteins are crucial for improving our understanding of human biology, developing new and better drugs, and advancing precision medicine. Proteomics technologies have lagged behind their genomics counterparts, but recent breakthroughs are now combining these methods in powerful ways. The journey to clinical utility, however, remains challenging. Association of a protein biomarker with any given disease process, for example, needs to be assessed in terms of disease-independent, confounding factors that may modulate protein expression levels among different individuals. Moreover, understanding whether an associated protein is causally involved in (or merely reflects) a disease process is extremely valuable information for identifying new drug targets. Our panelists will discuss how multi-omics and epidemiological approaches are accelerating important advances in the use of protein biomarkers for clinical research and pharmaceutical development.
Type of Medium:
Online Resource
ISSN:
0036-8075
,
1095-9203
DOI:
10.1126/science.357.6354.936-b
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2017
detail.hit.zdb_id:
128410-1
detail.hit.zdb_id:
2066996-3
detail.hit.zdb_id:
2060783-0
SSG:
11
Permalink
